Skip to main content
SpringerLink
Log in

Pretreatment serum GH levels and cardio-metabolic comorbidities in acromegaly; analysis of data from Iran Pituitary Tumor Registry

  • Research article
  • Published:
Journal of Diabetes & Metabolic Disorders Aims and scope Submit manuscript

Abstract

Background

Acromegaly is a rare chronic disabling disorder, in which growth hormone (GH) excess is associated with a range of clinical features and systemic complications. The present study aims to evaluate the association between pretreatment basal GH levels as well as GH levels after oral glucose tolerance test (OGTT) and cardio-metabolic comorbidities, including diabetes mellitus (DM), left ventricular hypertrophy (LVH) and hypertension (HTN) in patients with active acromegaly.

Methods

A retrospective study of the medical records regarding 113 patients with acromegaly registered at two main centers of Iran Pituitary Tumor Registry during 2011–2018.

Results

The mean age of the patients was 42.76 ± 11.6 (range: 21–72) years. Mean GH level at baseline was 21 ng/ml while nadir GH levels at 60 and 120 min after glucose were 6.95 and 9.05 ng/ml, respectively. There was a negative correlation between age and basal serum GH level (r= -0.196, p = 0.038). Hypertension and diabetes mellitus were detected in 26.8% and 19.7% of the patients. A positive correlation was detected between serum GH values and systolic blood pressure. There was not any significant difference in basal GH and GH post OGTT regarding DM, Diastolic blood pressure and LVH.

Conclusions

Our findings suggest that pretreatment basal GH levels are higher in younger patients with acromegaly. Furthermore, higher GH values (0, 60 and 120 min) during OGTT are associated with higher systolic blood pressure. A comprehensive evaluation of this population regarding comorbidities should be performed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Kauppinen-Mäkelin R, Sane T, Reunanen A, Välimäki MJ, Niskanen L, Markkanen H et al (2005) A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 90(7):4081–6

    Article  PubMed  Google Scholar 

  2. Melmed S (2006) Acromegaly. New England. J Med 355(24):2558–73

    CAS  Google Scholar 

  3. Colao A, Amato G, Pedroncelli A, Baldelli R, Grottoli S, Gasco V et al (2002) Gender-and age-related differences in the endocrine parameters of acromegaly. J Endocrinol Investig 25(6):532–8

    Article  CAS  Google Scholar 

  4. Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–51. https://doi.org/10.1210/jc.2014-2700

    Article  CAS  PubMed  Google Scholar 

  5. Holdaway IM (2007) Excess mortality in acromegaly. Horm Res 68(Suppl 5):166–72

    PubMed  Google Scholar 

  6. Ramos-Levi AM, Marazuela M (2017) Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management. Endocrine 55(2):346–59. https://doi.org/10.1007/s12020-016-1191-3

    Article  CAS  PubMed  Google Scholar 

  7. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D et al (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94(5):1509–17. https://doi.org/10.1210/jc.2008-2421

    Article  CAS  PubMed  Google Scholar 

  8. Vitale G, Pivonello R, Auriemma RS, Guerra E, Milone F, Savastano S et al (2005) Hypertension in acromegaly and in the normal population: prevalence and determinants. Clin Endocrinol 63(4):470–6. https://doi.org/10.1111/j.1365-2265.2005.02370.x

    Article  Google Scholar 

  9. Rieger A, Rainov NG, Ebel H, Sanchin L, Shibib K, Helfrich C et al (1997) Factors predicting pituitary adenoma invasiveness in acromegalic patients. Neurosurg Rev 20(3):182–7

    Article  CAS  PubMed  Google Scholar 

  10. Powlson AS, Gurnell M (2016) Cardiovascular Disease and Sleep-Disordered Breathing in Acromegaly. Neuroendocrinology 103(1):75–85. https://doi.org/10.1159/000438903

    Article  CAS  PubMed  Google Scholar 

  11. Bondanelli M, Ambrosio MR, degli Uberti EC (2001) Pathogenesis and prevalence of hypertension in acromegaly. Pituitary 4(4):239–49

    Article  CAS  PubMed  Google Scholar 

  12. Frara S, Maffezzoni F, Mazziotti G, Giustina A (2016) Current and emerging aspects of diabetes mellitus in acromegaly. Trends Endocrinol Metab 27(7):470–83. https://doi.org/10.1016/j.tem.2016.04.014

    Article  CAS  PubMed  Google Scholar 

  13. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J et al (2014) 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311(5):507–20. https://doi.org/10.1001/jama.2013.284427

    Article  CAS  PubMed  Google Scholar 

  14. American Diabetes A (2015) (2) Classification and diagnosis of diabetes. Diabetes Care 38 Suppl(Supplement 1):S8–S16. https://doi.org/10.2337/dc15-S005

    Article  Google Scholar 

  15. Haliloglu O, Kuruoglu E, Ozkaya HM, Keskin FE, Gunaldi O, Oz B et al (2016) Multidisciplinary approach for acromegaly: A single tertiary center’s experience. World Neurosurg 88:270–6. https://doi.org/10.1016/j.wneu.2015.12.092

    Article  PubMed  Google Scholar 

  16. Petersenn S, Buchfelder M, Gerbert B, Franz H, Quabbe HJ, Schulte HM et al (2009) Age and sex as predictors of biochemical activity in acromegaly: analysis of 1485 patients from the German Acromegaly Register. Clin Endocrinol 71(3):400–5. https://doi.org/10.1111/j.1365-2265.2009.03547.x

    Article  CAS  Google Scholar 

  17. Petrossians P, Daly AF, Natchev E, Maione L, Blijdorp K, Sahnoun-Fathallah M et al (2017) Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database. Endocr Relat Cancer 24(10):505–18. https://doi.org/10.1530/ERC-17-0253

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25(1):102–52. https://doi.org/10.1210/er.2002-0022

    Article  CAS  PubMed  Google Scholar 

  19. Schilbach K, Nicolay SS, Haenelt M, Lechner A, Gar C, Schopohl J et al (2017) Diagnosis of acromegaly: Sex and BMI are the major determinants of growth hormone suppression during oral glucose tolerance test (OGTT)

  20. Dal J, Feldt-Rasmussen U, Andersen M, Kristensen L, Laurberg P, Pedersen L et al (2016) Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study. Eur J Endocrinol 175(3):181–90

    Article  CAS  PubMed  Google Scholar 

  21. Park JY, Kim JH, Kim SW, Chung JH, Min Y-K, Lee M-S et al (2014) Using Growth Hormone Levels to Detect Macroadenoma in Patients with Acromegaly. Endocrinol Metab 29(4):450–6

    Article  Google Scholar 

  22. Iuchi S, Saeki N, Uchino Y, Higuchi Y, Tatsuno I, Nakamura S et al (2000) Cavernous sinus invasion and tumor proliferative potential of growth hormone-producing pituitary tumors. Endocr J 47(Suppl):77–9

  23. Alexopoulou O, Bex M, Kamenicky P, Mvoula AB, Chanson P, Maiter D (2014) Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary 17(1):81–9. https://doi.org/10.1007/s11102-013-0471-7

    Article  CAS  PubMed  Google Scholar 

  24. Arosio M, Reimondo G, Malchiodi E, Berchialla P, Borraccino A, De Marinis L et al (2012) Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol 167(2):189–98. https://doi.org/10.1530/eje-12-0084

    Article  CAS  PubMed  Google Scholar 

  25. Fieffe S, Morange I, Petrossians P, Chanson P, Rohmer V, Cortet C et al (2011) Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. Eur J Endocrinol 164(6):877–84

    Article  CAS  PubMed  Google Scholar 

  26. Portocarrero-Ortiz LA, Vergara-Lopez A, Vidrio-Velazquez M, Uribe-Diaz AM, Garcia-Dominguez A, Reza-Albarran AA et al (2016) The Mexican Acromegaly Registry: Clinical and Biochemical Characteristics at Diagnosis and Therapeutic Outcomes. J Clin Endocrinol Metab 101(11):3997–4004. https://doi.org/10.1210/jc.2016-1937

    Article  CAS  PubMed  Google Scholar 

  27. Espinosa-de-los-Monteros AL, Gonzalez B, Vargas G, Sosa E, Mercado M (2011) Clinical and biochemical characteristics of acromegalic patients with different abnormalities in glucose metabolism. Pituitary 14(3):231–5. https://doi.org/10.1007/s11102-010-0284-x

    Article  CAS  PubMed  Google Scholar 

  28. Fedrizzi D, Rodrigues TC, Costenaro F, Scalco R, Czepielewski MA (2011) Hypertension-related factors in patients with active and inactive acromegaly. Arq Bras Endocrinol Metabol 55(7):468–74

    Article  PubMed  Google Scholar 

  29. Amado A, Araújo F, Carvalh D (2018) Cardiovascular risk factors in acromegaly: What’s the impact of disease control? Exp Clin Endocrinol Diabetes 26(8):505–512

  30. Sacca L, Napoli R, Cittadini A (2003) Growth hormone, acromegaly, and heart failure: an intricate triangulation. Clin Endocrinol 59(6):660–71. https://doi.org/10.1046/j.1365-2265.2003.01780.x

    Article  CAS  Google Scholar 

  31. Sardella C, Cappellani D, Urbani C, Manetti L, Marconcini G, Tomisti L et al (2016) Disease activity and lifestyle influence comorbidities and cardiovascular events in patients with acromegaly. Eur J Endocrinol 175(5):443–53. https://doi.org/10.1530/eje-16-0562

    Article  CAS  PubMed  Google Scholar 

  32. Ohtsuka H, Komiya I, Aizawa T, Yamada T (1995) Hypertension in acromegaly: hereditary hypertensive factor produces hypertension by enhancing IGF-I production. Endocr J 42(6):781–7

    Article  CAS  PubMed  Google Scholar 

  33. Vitale G, Galderisi M, Pivonello R, Spinelli L, Ciccarelli A, De Divitiis O et al (2004) Prevalence and determinants of left ventricular hypertrophy in acromegaly: impact of different methods of indexing left ventricular mass. Clin Endocrinol 60(3):343–9. https://doi.org/10.1111/j.1365-2265.2004.01985.x

    Article  Google Scholar 

  34. Colao A, Marzullo P, Di Somma C, Lombardi G (2001) Growth hormone and the heart. Clin Endocrinol 54(2):137–54. https://doi.org/10.1046/j.1365-2265.2001.01218.x

    Article  CAS  Google Scholar 

Download references

Funding

This study was funded by Tehran University of Medical Sciences (TUMS) and Endocrinology and Metabolism Research Institute affiliated to TUMS (Grant number 1396-01-98-2146).

Author information

Authors and Affiliations

  1. Internal Medicine, Medicine Faculty, Tehran University of Medical Sciences, Tehran, Iran

    Leila Hedayati Zafarghandi & Milad Fooladgar

  2. Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences (IUMS), Tehran, Iran

    Mohammad Ebrahim Khamseh & Nahid Hashemi Madani

  3. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Shariati Hospital, Tehran University of Medical Sciences, 14114-13137, 5th floor, North Kargar Ave. P.C., Tehran, Iran

    Shahrzad Mohseni, MohammadReza Mohajeri-Tehrani & Nooshin Shirzad

  4. Non-communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran

    Mostafa Qorbani

  5. Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

    Mostafa Qorbani

  6. Endocrine Research Center, Valiasr Hospital, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

    Mahboobeh Hemmatabadi

Authors
  1. Leila Hedayati Zafarghandi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohammad Ebrahim Khamseh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Milad Fooladgar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shahrzad Mohseni
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mostafa Qorbani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nahid Hashemi Madani
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mahboobeh Hemmatabadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. MohammadReza Mohajeri-Tehrani
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Nooshin Shirzad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to MohammadReza Mohajeri-Tehrani or Nooshin Shirzad.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

*This paper is derived from the dissertation of Dr. Leila Hedayati for obtaining internal medicine specialty.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hedayati Zafarghandi, L., Khamseh, M.E., Fooladgar, M. et al. Pretreatment serum GH levels and cardio-metabolic comorbidities in acromegaly; analysis of data from Iran Pituitary Tumor Registry. J Diabetes Metab Disord 19, 319–325 (2020). https://doi.org/10.1007/s40200-020-00512-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40200-020-00512-5

Keywords

Search

Navigation